Articles By Rob Wright, Chief Editor
Building A COVID-19 Vaccine Company In A Few Months6/1/2021
Mei Mei Hu, J.D., and her husband Lou Reese know what it’s like to develop a drug during a pandemic. Nearly 20 years ago they helped develop a vaccine and antibody test for the SARS outbreak. But now they were considering starting a COVID-19 vaccine company — during 2020.
How An Industry Outsider Became A Biopharma CEO5/3/2021
John Fowler had never worked in biopharma before. That didn’t stop his best friend — a scientist — from asking Fowler to lead the biotech startup he had been working on. It was a risk to both the company’s future — and their friendship.
From Aha Moment To $10 Billion Biopharma5/3/2021
In 2012 Neil Kumar, Ph.D. read an article in Nature Biotechnology and was so inspired by the paper’s theories on drug discovery and development, that he eventually decided to quit his job and start his own biopharma called BridgeBio.
Got Your Zoom On?5/3/2021
The majority of my interviews have been over the phone. As for how many interviews for feature articles I’ve conducted via Zoom, the number is exactly two — both appearing in this issue.
How Has The Pandemic Impacted You — And Your People?4/6/2021
Disruption of life routines by COVID-19 provide a CNS opportunity on multiple fronts.
The Making Of A CFO — A Conversation With J&J’s Joseph Wolk4/1/2021
Joe Wolk’s father spent 40 years working at the nearby J&J manufacturing facility. Now, Joe has reached the top of the organization as CFO. His path getting there, though, didn’t start in pharma.
The Streak — Is Over4/1/2021
Our previous 16 regular issues of LSL (excluding the annual outlook issue) featured a biopharmaceutical company CEO on the cover. But our cover features aren’t limited to the CEO, as this month’s issue shows with our feature on J&J’s CFO Joe Wolk.
Is Biopharma's Reputation Back?3/26/2021
While biopharma's response to COVID-19 has started to turnaround the industry's sagging reputation, one successful response to one crisis does not a reputation save.
Enanta Pharmaceuticals: From Failure To Formidable3/1/2021
While working at a VC firm, Jay Luly, Ph.D., was tasked with assessing if Enanta Pharmaceuticals could be turned around, or if it should be shut down. Today the company is probably one of the most productive Big Pharma R&D engines you’ve never heard of — until now.